Admission to the intensive care unit (ICU) is a standard of care after transcatheter aortic valve implantation (TAVI); however, the improvement of the procedure and the need to minimize the unnecessary use of medical resources call into question this strategy. We evaluated prospectively 177 consecutive patients who underwent TAVI. Low-risk patients, admitted to conventional cardiology units, had stable clinical state, transfemoral access, no right bundle branch block, permanent pacing with a self-expandable valve, and no complication occurring during the procedure. High-risk patients included all the others transferred to ICU. In-hospital events were the primary end point (Valve Academic Research Consortium 2 criteria). The mean age of patients was 83.5 ± 6.5 years, and the mean logistic EuroSCORE was 14.6 ± 9.7%. The balloon-expandable SAPIEN 3 valve was mainly used (n = 148; 83.6%), mostly with transfemoral access (n = 167; 94.4%). Among the 61 patients (34.5%) included in the low-risk group, only 1 (1.6%) had a minor complication (negative predictive value 98.4%, 95% confidence interval [CI] 0.91 to 0.99). Conversely, 31 patients (26.7%) from the high-risk group had clinical events (positive predictive value 26.7%, 95% CI 0.19 to 0.35), mainly conductive disorders requiring pacemaker (n = 26; 14.7%). In multivariate analysis, right bundle branch block (odds ratio [OR] 14.1, 95% CI 3.5 to 56.3), use of the self-expandable valve without a pacemaker (OR 5.5, 95% CI 2 to 16.3), vitamin K antagonist treatment (OR 3.8, 95% CI 1.1 to 12.6), and female gender (OR 2.6, 95% CI 1.003 to 6.9) were preprocedural predictive factors of adverse events. In conclusion, our results suggested that TAVI can be performed safely without ICU admission in selected patients. This strategy may optimize efficiency and cost-effectiveness of procedures.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.amjcard.2016.04.019 | DOI Listing |
J Chin Med Assoc
November 2024
Department of Cardiology, West China Hospital, Sichuan University, Chengdu, China.
Since the first transcatheter aortic valve replacement (TAVR) was performed in China in 2010, TAVR has developed rapidly. However, the temporal trends in the 1-year prognosis after TAVR in China have not been described. This study enrolled patients treated at a high-volume Chinese TAVR center, West China Hospital, between 2015 and 2022, to analyze and characterize the temporal trends in 1-year outcomes.
View Article and Find Full Text PDFAnn Thorac Surg Short Rep
December 2024
Department of Cardiovascular Surgery, Tokyo Women's Medical University, Tokyo, Japan.
In the valve-in-valve transcatheter aortic valve replacement (ViV-TAVR) era, implanting a larger-sized valve during the initial aortic valve replacement is important. For smaller aortic annuli, combining aortic annular and left ventricular outflow tract (LVOT) enlargement is essential. The Y-incision procedure helps achieve implantation of a 2-size larger valve.
View Article and Find Full Text PDFAnn Thorac Surg Short Rep
December 2024
Division of Adult Cardiothoracic Surgery, Department of Surgery, University of California, San Francisco, San Francisco, California.
This report presents the case of a 66-year-old man with acute torrential aortic insufficiency after a Ross procedure 20 years earlier, a biologic aortic valve replacement 16 years earlier, and a transcatheter valve-in-valve 4 years earlier. He underwent third-time sternotomy, revealing that the pulmonary autograft was heavily calcified and frozen to the homograft. The previous transcatheter valve-in-valve was explanted.
View Article and Find Full Text PDFAnn Thorac Surg Short Rep
December 2024
Department of Cardiology, Puerta de Hierro University Hospital, Madrid, Spain.
We report a case of a woman who underwent mitral ring and tricuspid annuloplasty. Two months later, she presented with acute heart failure secondary to severe aortic regurgitation, which was a complication of the cardiac surgery. Given the high surgical risk of reoperation in this the patient, she underwent transcatheter aortic valve implantation, with a good result.
View Article and Find Full Text PDFAnn Thorac Surg Short Rep
December 2024
Department of Cardiovascular Surgery, Iwaki City Medical Center, Iwaki, Japan.
A 90-year-old man received a diagnosis of ascending aortic pseudoaneurysms after transcatheter aortic valve implantation (TAVI) using an Evolut PRO valve (Medtronic). Plug closure of the pseudoaneurysms was successfully performed, and the symptoms improved after the procedure. However, on postoperative day 4, the patient experienced sudden massive hemoptysis and died.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!